Literature DB >> 17242670

Tolerance to chemotherapy in elderly patients with cancer.

Ulrich Wedding1, Friedemann Honecker, Carsten Bokemeyer, Ludger Pientka, Klaus Höffken.   

Abstract

BACKGROUND: Due to demographic changes, the number of elderly people with cancer will increase in the next decades. In the past, elderly patients with cancer were often excluded from clinical trials. Chronological age has been considered a risk factor for increased toxicity and reduced tolerance to chemotherapy.
METHODS: We present a review on toxicity of chemotherapy and factors associated with toxicity in elderly patients with cancer, and we discuss chemotherapeutic agents and treatment options in treating this patient population.
RESULTS: Age is a risk factor for increased toxicity to chemotherapy and decreased tolerance. However, few trials have been reported with adjustment for age-associated changes such as impairment of functional status and increased comorbidity, which also show an independent association with increased toxicity. Published data may include several biases, such as referral and publication bias.
CONCLUSIONS: Decision making in elderly cancer patients should be based on the results of a geriatric assessment. Patients with few or no limitations should be treated as younger patients are treated. Data with a high level of evidence are unavailable for patients showing moderate or severe limitations in a geriatric assessment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242670     DOI: 10.1177/107327480701400106

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  37 in total

1.  Treatment of head and neck cancer in the elderly: European Consensus (panel 6) at the EUFOS Congress in Vienna 2007.

Authors:  Reidar Grénman; Dominique Chevalier; Vincent Gregoire; Eugene Myers; Simon Rogers
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-09       Impact factor: 2.503

2.  Senior adult oncology.

Authors:  Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

Review 3.  Older adults and cancer treatment.

Authors:  Barbara Given; Charles W Given
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

Review 4.  Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence.

Authors:  Gonzalo Tapia Rico; Amanda R Townsend; Vy Broadbridge; Timothy J Price
Journal:  Drugs Aging       Date:  2017-03       Impact factor: 3.923

5.  A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).

Authors:  Satoru Miura; Makoto Maemondo; Akira Iwashima; Toshiyuki Harada; Shunichi Sugawara; Kunihiko Kobayashi; Akira Inoue; Taku Nakagawa; Yuichi Takiguchi; Hiroshi Watanabe; Takashi Ishida; Masaki Terada; Hiroshi Kagamu; Akihiko Gemma; Hirohisa Yoshizawa
Journal:  Invest New Drugs       Date:  2017-02-01       Impact factor: 3.850

6.  Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up.

Authors:  Kerri M Clough-Gorr; Andreas E Stuck; Soe Soe Thwin; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

7.  Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.

Authors:  Mark Zaki; Michael Dominello; Gregory Dyson; Shirish Gadgeel; Antoinette Wozniak; Steven Miller; Peter Paximadis
Journal:  Clin Lung Cancer       Date:  2016-07-22       Impact factor: 4.785

8.  Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

Authors:  Maria De Santis; Joaquim Bellmunt; Graham Mead; J Martijn Kerst; Michael Leahy; Pablo Maroto; Iwona Skoneczna; Sandrine Marreaud; Ronald de Wit; Richard Sylvester
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

Review 9.  [Small cell lung cancer].

Authors:  Stefan Hoschek; Ursula Hoschek-Risslegger; Michael Fiegl; August Zabernigg; Georg Pall; Thomas Auberger; Eberhard Gunsilius; Thomas Schmid; Herbert Jamnig; Wolfgang Hilbe
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 10.  Aging, nutrient signaling, hematopoietic senescence, and cancer.

Authors:  Priya Balasubramanian; Valter D Longo
Journal:  Crit Rev Oncog       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.